Sugi Predict

Sugi Predict / Compounds / SCHEMBL4597784

SCHEMBL4597784

SCHEMBL4597784

CS(=O)(=O)c1ccc(C(=O)O)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ PTK2B Q14289 2/20 0.46
▸ CDC25B P30305 1/20 0.44
▸ PKM P14618 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ NR1H4 Q96RI1 1/20 0.42
▸ NEU3 Q9UQ49 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ FABP4 P15090 1/20 0.41
▸ EGLN1 Q9GZT9 1/20 0.40
▸ PIK3CD O00329 1/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ PIK3CB P42338 1/20 0.40
▸ PIK3CG P48736 1/20 0.40
▸ ACLY P53396 1/20 0.40
▸ CCR2 P41597 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29499772 1.00 LMNA (0.51) LMNAMAPK1HTTRAB9APTK2B
SCHEMBL6723560 0.85 ALDH1A1 (0.44) RAB9ASMN1; SMN2PIK3CDPIK3CAPIK3CB
SCHEMBL2593426 0.85 PTK2B (0.58) LMNAMAPK1HTTRAB9APTK2B
SCHEMBL15465419 0.84 CCR2 (0.42) PIK3CDPIK3CAPIK3CBPIK3CGCCR2
SCHEMBL27560170 0.83 ABCC9 (0.49) LMNAMAPK1RAB9ASMN1; SMN2KMT2A
SCHEMBL5405584 0.82 CDC25B (0.53) HTTPTK2BCDC25BPKMNEU3
SCHEMBL15573975 0.82 LMNA (0.49) LMNAMAPK1HTTRAB9APTK2B
SCHEMBL29787231 0.81 NEU3 (0.57) LMNAMAPK1HTTRAB9APTK2B
SCHEMBL3160473 0.81 LMNA (0.47) LMNAMAPK1HTTRAB9APTK2B
SCHEMBL2777527 0.81 NEU3 (0.57) LMNAMAPK1HTTRAB9APTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114206335-B KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2025-03-11 — — CN disclosed
EP-4446314-A2 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2024-10-16 — — EP disclosed
EP-3962479-B1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2024-07-24 — — EP disclosed
CN-112218627-B Prodrugs and their medical use 康维尔特制药有限公司 2024-04-16 — — CN disclosed
US-20220280476-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-09-08 — — US disclosed
US-20220280476-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-09-08 — — US disclosed
CN-114206335-A KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2022-03-18 — — CN disclosed
US-20210205299-A1 PRODRUGS AND MEDICAL USES THEREOF CONVERT PHARMACEUTICALS (BE) 2021-07-08 — — US disclosed
EP-3801481-A1 PRODRUGS AND MEDICAL USES THEREOF Convert Pharmaceuticals SA (BE) 2021-04-14 — — EP disclosed
CN-112218627-A Prodrugs and their use in medicine 康维尔特制药有限公司 2021-01-12 — — CN disclosed
EP-2686325-A1 MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2014-01-22 — — EP disclosed
US-20120264749-A1 MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2012-10-18 — — US disclosed
WO-2012125613-A1 MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-20 — — WO disclosed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 — — US disclosed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 — — US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 — — US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 — — US disclosed
EP-1907383-A1 GPCR AGONISTS Prosidion Limited (GB) 2008-04-09 — — EP disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 — — WO disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220280476-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 LMNA 1423/4885MAPK1 890/4885HTT 141/4885
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 LMNA 4210/4885MAPK1 863/4885HTT 3646/4885
US-20210205299-A1 PRODRUGS AND MEDICAL USES THEREOF GLS, BAD, WEE1 LMNA 2777/4885MAPK1 3672/4885HTT 3610/4885
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN1B, SCN1A, SCN2B LMNA 3683/4885MAPK1 1136/4885HTT 956/4885
US-20120264749-A1 MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS KCNJ2, TRPM5, KCNQ1 LMNA 2005/4885MAPK1 2895/4885HTT 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.